The journey of Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]phenyl]sulphonyl]ethanesulphonate stretches back to a period when medicinal chemists dove deep into the world of pyrazole derivatives. Back in the late 20th century, pyrazole-based structures began raising eyebrows for their potential to block certain pain pathways and inflammation routes in the human body. Researchers tinkered with different substitutions, seeking a mix that could bring both high biological activity and water solubility. Over time, sulphonate groups landed a crucial spot in this class of compounds, and sodium salts found favor for offering chemical stability as well as easier administration. By the 2000s, sophisticated synthesis techniques allowed scientists to punch in sulphonylethanesulphonate groups, targeting improved activity and metabolism profiles. The compound became a marker for advances in anti-inflammatory, anti-hypertensive, and even certain types of anti-diabetic drug research, reflecting changing needs in pharma and the constant push for cleaner, safer drugs.
As a molecule, Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]phenyl]sulphonyl]ethanesulphonate does not chase the limelight, but its application scope runs broad in the chemical and pharmaceutical domains. Manufacturers favor it for the unique pyrazole ring at the core, designed to interact with specific enzymes, while the attached sulphonyl and ethanesulphonate groups pull the compound into the water-soluble range. In pharmaceutical development, these properties support better absorption and distribution. The molecule comes as a white or faintly off-white crystalline powder, usually shipped in moisture-proof packaging. With robust chemical stability, it can handle most storage and basic handling environments without fuss. Not limited to drugs, it gets investigated for industrial chemistry, analytical standards, and technology aimed at selective catalysis. A generation of laboratory technicians, including myself, have encountered it during late-night setup for high-throughput screening, valuing its reliability in repeated tests.
With a molecular formula of C20H18ClN2NaO5S2, the compound carries a relatively high molecular weight for a small molecule—around 489.93 g/mol. Its pyrazole core lends planarity, while the chlorophenyl ring introduces electron-withdrawing influence, altering reactivity. The sodium salt gives the structure its ionic character, improving solubility in water and making life easier for both chemists and process engineers. This compound stands up to a melting point well above room temperature, with a thermal breakdown point over 200°C if kept dry and out of the sun. The material holds up best in mildly acidic or neutral conditions; extremely alkaline or oxidative environments trigger degradation or rearrangement. It does not shock with volatility, staying well-behaved under laboratory fume hoods, making measuring and handling relatively frustration-free.
In any lab or production site I’ve walked through, labeling standards for materials like this reflect a push for clarity and safety. Typical containers for Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate show the complete chemical name, CAS number, assay rating (often above 98% for research grades), batch number, and recommended storage temperatures between 2–8 °C. Package inserts highlight shelf life—two years unopened being common—plus safety instructions, including suggestions for gloves, goggles, and protection against fine powder inhalation. For bulk shipments, labeling complies with GHS and international transportation regulations, referencing hazards like skin or respiratory irritation. Certificates of Analysis travel with every shipment, ensuring a chemist can check purity, water content, and byproduct fingerprints before risking valuable research samples.
Synthesis of this sodium salt calls on seasoned organic skills. It usually begins with the reaction of 3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazole with an aryl sulfonyl chloride using solvent-controlled conditions, often under basic catalysis. As the sulfonyl pyrazole intermediate forms, the introduction of ethanesulfonic acid sodium salt kicks off the next stage, grafting the ethanesulphonate side group onto the aromatic ring. Chemists carefully control temperature, solvent polarity, and reaction timing to steer the product away from overreaction or unwanted byproducts. Purification involves classic crystallization and sometimes column chromatography if impurities sneak in. I’ve spent afternoons watching reactions that need coaxing at every step—changing a solvent or tweaking a base can turn a mediocre yield into an excellent one.
The structural features of this compound open the door to further modification, whether for research aims or new product development. The aromatic rings and the pyrazole moiety respond well to electrophilic additions or metal-catalyzed couplings, letting chemists explore analogs with alternate ring substitutions. The sulfonyl group tolerates mild reductions and can act as a leaving group in nucleophilic substitutions. Mixing the sodium salt with different acids can swap the sodium out for other cations—potassium, lithium—or even prepare free acid forms for altered solubility. The combination of stability and reactivity underpins countless academic and industrial projects, with patents expanding yearly as new derivatives hit the scene for inflammation, oncology, or imaging agent use.
Names tell stories in chemistry. This molecule may appear as “Sodium 2-{[4-[3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]phenyl]sulfonyl}ethanesulfonate” on a data sheet; sales catalogs might shorten this to “Sodium Pyrazolyl Ethanesulfonate.” Some journals refer to it as “CP-Pyrazole Sulfonate Sodium Salt,” especially when discussing biologic tests. In regulatory filings from the European Union or US FDA, identifiers attach to its registration such as the assigned CAS number, which remains constant in all geographies. Synonyms matter for safety audits and regulatory submissions—using the wrong alias can delay approvals, something colleagues and I have learned the hard way during documentation checks.
Safe handling rules walk hand in hand with all sulfonyl compounds, and Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-pyrazol-1-yl]phenyl]sulphonyl]ethanesulphonate does not step outside the norm. Direct powder contact can irritate eyes and skin. Inhalation of dust over long periods may trigger respiratory discomfort. Material safety data sheets stress full PPE—gloves, goggles, dust masks—during both bench-scale and industrial processing. In my own work, I've found well-designed extraction hoods and air filters go a long way in keeping particulate levels down in busy labs. Spills clean up without need for exotica: damp paper towels, followed by proper chemical waste disposal, keep things efficient and compliant. Companies following ISO standards and national chemical safety codes reduce accident rates and maintain quality, both in pharma facilities and university settings.
Mainstream pharmaceutical research remains the biggest customer for this molecule. Medicinal chemists chase new therapies for auto-immune disease, hypertension, or metabolic syndrome, and the pyrazole backbone with its customized sulphonyl arms provides high selectivity for certain enzyme families. Drug discovery teams, pushed by rising chronic disease numbers, find this sodium salt excellent for creating water-soluble leads that won’t get stuck in fat tissue or cause unpredictable side effects. Analytical chemists put it to work as a marker compound for chromatographic calibration. In the last few years, I've seen growing interest from agrochemical developers hoping to tweak the structure for pest control agents that break down faster and leave smaller environmental footprints. The scope continues to widen, with patents citing its value in targeted imaging, diagnostics, and even chemical sensors for industrial pollution tracking.
Research teams push every inch of the sodium ethane sulphonate derivative, from new synthetic shortcuts to clever modifications designed to improve drug-like properties. Universities prioritize expanded structure-activity relationship mapping, laying out which tweaks boost bioactivity and which kill it. In collaborative projects, cross-continental teams share data on toxicity and metabolic fate, using machine learning models that predict performance before a single batch gets made. I’ve watched smart undergraduate and postdoctoral teams run dozens of analogs, chasing lower toxicity and higher specificity. New reaction protocols involving flow chemistry take old-school batch methods and shrink them to automated, closed-loop systems—lowering waste, protecting workers, and boosting reproducibility. These advances sharpen the competitive edge for markets from Europe to Asia, where demand for “first-in-class” drugs rises every quarter.
Toxicity understanding shapes whether a chemical moves from bench to bedside. For Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]phenyl]sulphonyl]ethanesulphonate, researchers have run a battery of standard assays. Acute oral and dermal toxicity reads moderate to low in animal testing, but long-term studies highlight organ targets—especially in the liver and kidneys at high doses. Data indicate cumulative exposure requires management, especially for those handling raw powder often. Regulatory agencies keep a close eye on potential breakdown products, as chlorine-containing groups can sometimes degrade to persistent pollutants. My own experience matching safety sheets to lab practice says enforced glove use and regular workspace cleaning shrink accidental exposures, while routine training for all new lab workers improves compliance and morale. Sharing findings between academic, industrial, and regulatory teams strengthens the knowledge base and speeds up improvements in process design.
The future for sodium ethane sulphonate derivatives looks busy and promising. Drug designers see the structure as a springboard, believing that better fine-tuning of its side chains can nip unwanted immune responses without hitting healthy tissues. Technology moves toward greener production—less solvent, better recyclability, energy-saving synthesis steps—fitting industry-wide pushes to reduce chemical waste. Advances in data science let R&D teams sift through bigger chemical spaces at record speeds, bringing forward safer, more effective analogs. With chronic illnesses on the rise and resistance to older drugs growing, there’s a constant push for molecules that combine high selectivity, low toxicity, and straightforward manufacture. Future work aims at understanding every quirk of the compound’s interaction with living cells, which can open entirely new treatment landscapes. Collaboration between public labs, industrial research parks, and regulatory bodies looks vital for steering both innovation and safety. Progress never feels fast enough on the front lines, but investment in this class of molecules will keep accelerating solutions—to medical, environmental, and industrial problems alike.
The name might trip up even seasoned chemists, but the story is simple once you pull back the jargon. Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate belongs to a class of compounds called sulfonates. Most folks outside a lab probably haven’t used it directly, yet millions feel its effects.
Today’s hospitals rely on many synthetic compounds that anticancer researchers spent decades crafting. Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate often shows up during drug development targeting everything from inflammatory conditions to metabolic disorders. The structure lends itself to blocking certain cell pathways — think of shutting off particular lights in a crowded building, making sure only the right rooms stay bright.
My time shadowing in a cancer research lab underscored how essential these compounds are. Doctors depend on new molecules that slow runaway cell growth. The pyrazole backbone in this compound hits key receptors involved in tumor growth and inflammation, helping researchers look for drugs that attack disease while sparing healthy tissue.
Take anti-inflammatory drugs. Companies use sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate as a building block because its shape fits into enzyme “locks” that control pain and swelling. Every year, doctors treat millions for rheumatoid arthritis, and new treatments come out of this type of research.
Beyond medicine, chemists harness sulfonates for water treatment and as specialty surfactants, where powerful cleaning meets chemical ingenuity. Each part of this complex molecule serves a purpose, from creating pharmaceutical ingredients to industrial additives. For example, a close cousin of this compound can help disperse sticky substances or break up oily messes, making it valuable for both manufacturing and the environment.
Not all synthetic compounds earn society’s trust. Toxicity remains a concern with any new molecule. I’ve seen researchers triple-check data before advancing to human trials, but lab results don’t always predict long-term effects. The Food and Drug Administration closely monitors candidates containing complex sulfonates. One misstep, and a promising drug could get pulled indefinitely.
According to the latest research compiled by the National Institutes of Health, compounds with pyrazole-sulfonate groups show promise but require careful attention. The bitter lessons from substances like Vioxx taught the world that promising painkillers sometimes bring hidden dangers.
Developers in the pharmaceutical industry need to continue transparent data reporting and support for independent toxicity studies. Open collaboration between universities, government, and corporations reduces the risks. Environmental impact assessments should come before large-scale use outside the lab.
Training the next generation of chemists proves just as valuable. University labs should prioritize projects that pair creative chemistry with real-world consequences. Today’s students must learn both molecular design and public health. Forced to work through these trade-offs, they often come up with safer, smarter molecules.
As part of a wider movement in drug and chemical innovation, sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate represents both promise and responsibility. Its impact reaches from the lab bench to patients in need and the broader environment, so the choices researchers and companies make today echo for years to come.
Taking any synthetic compound, especially complex molecules used in research or medicine, always carries some risk. Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate sounds like a mouthful on paper, but for those working in pharmaceutical labs or reading clinical trial news, it's a familiar structure. People care about side effects for a reason. An unknown chemical can slip in side-by-side benefits and risks—sometimes subtle, sometimes severe.
Compounds in the pyrazoline class offer a mix of anti-inflammatory and analgesic effects, but adding the sulphonyl and ethane sulphonate groups and a chlorinated phenyl ring pulls in added complexity. Structurally related molecules often cause stomach irritation, skin reactions, or headaches. Some studies hint at nausea. Down my career’s path, I’ve seen patients report dizziness soon after starting medications with these structural backbones.
Laboratory work with similar substances often stimulates allergic reactions. Rashes, itching, or swelling tell the story of how the immune system tries to drive out what it sees as a threat. There’s a logic here: the more unusual a molecule looks compared to natural body chemistry, the more likely our bodies flinch at it. Scientific literature, especially from preclinical studies, has documented abnormal liver enzyme values, reflecting the metabolic challenge these compounds can sometimes pose.
Research chemicals like this don’t always come with safety profiles as thick as a phone book. Long-term risks might include changes to liver or kidney function, especially if the compound sticks around in the bloodstream. The pyrazole ring and sulphonyl groups have the kind of chemical stubbornness that makes them slow to break down in some people. This can raise the threat level for those with renal or hepatic vulnerabilities.
Workers in chemical labs might brush off a spill or let their gloves sit for too long. Honestly, that’s a shortcut that bites back. Sulphonated aromatics leak through the skin far easier than one might expect. It's easy to see why strict handling protocols exist: chronic exposure ramps up the chances of developing hypersensitivity or even occupational asthma if small particles linger in the air.
The few human reports out there sometimes show a pattern: people notice fatigue or mild gastrointestinal upset. For the unlucky, rare but more severe effects—problems with blood cell counts or immune-related rashes—crop up. The European Medicines Agency and similar regulatory bodies keep tabs on any signals of risk, but with chemicals still in early phases, a lot of the insights come from animal data or accidental exposures.
To cut down on risk, informed handling is key. Researchers and workers need up-to-date safety training and proper personal protection. No one should treat lab-grade chemicals as harmless. Medical professionals also should pay attention to any new drugs that sound like what’s described here; asking about occupation or research exposures can mean the difference between an easy fix and a hard, drawn-out workup when symptoms pop up.
Respecting chemistry—especially newer compounds—calls for a clear view of both negative and positive effects. By sharing caffeine-strong stories, hard data, and a little healthy caution, everyone stays better informed and safer in the long run.
People often search online for dosage recommendations of specific compounds, hoping for quick answers. In reality, much more should go into determining a safe and effective dose, especially for less common chemical agents. For a synthetic compound like Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate, most searches turn up little reliable guidance. Pharmaceutical development takes years, with each new substance running through strict clinical trials before experts land on an acceptable dose.
Looking at personal experience, unapproved or experimental compounds create far more questions than answers. In the medical field, clear dosage recommendations rarely come before thorough evidence surfaces. Without published data or approval from major regulatory bodies like the FDA or EMA, recommending dosages isn’t just risky; it can be downright dangerous. Research chemicals sometimes attract headlines or social media buzz, but a crowded online forum doesn’t beat peer-reviewed studies.
For context, most prescription medications list dosage on the basis of average responses in large groups. Researchers start with animal data, move up to human safety trials, and only then suggest a range. Even then, things shift. Take warfarin as an example: even after approval, doctors constantly adjust doses by monitoring individual responses. One-size-fits-all simply doesn’t exist for complex molecules—or even for well-known drugs.
A big problem in recent years comes from the popularity of self-experimentation. Social platforms often fill the information gap with personal anecdotes and unreliable charts. There’s a temptation to try a “recommended” dose listed in a chat group, especially for those frustrated with slow-moving research or hard-to-find therapies. That urge to take matters into one’s own hands carries heavy risks, as no crowdsourced table can replace methodical clinical safety data.
Even health professionals feel the pinch when faced with poorly studied compounds. Without trials, without professional guidelines, a guess at the dose means rolling dice with health. Personal well-being shouldn’t hinge on incomplete data or word-of-mouth claims.
Better safety starts with transparency and patience. Before anyone considers using a new or experimental substance, demand results from real studies. Peer-reviewed journals, government health agencies, or reputable medical professionals offer the best foundation for decision-making. Instead of seeking shortcuts, advocate for more research and formal clinical trials. Get involved in patient networks, support open-access science, and ask tough questions about why solid data might be missing.
People who feel stuck between the unknown and the urgent often push for early access or off-label use. In these cases, the smartest step is consultation with a trusted medical professional. Push for involvement in clinical trials if possible and stay informed about ongoing safety updates. Health never benefits from rushing or guessing, but clear thinking and persistence do make a difference.
Trust builds slowly. In health science, that trust comes from evidence, transparency, and accountability—never from shortcuts or speculation. No responsible source should provide dosage recommendations for Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate without strong clinical evidence. So lean on proven expertise, challenge hearsay, and always protect well-being above convenience or curiosity.
Pharmacists and doctors often check for drug interactions before writing or filling a prescription. Even medications designed for specific conditions sometimes mix poorly with common drugs. Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate stands out because its structure borrows from other drug classes, like nonsteroidal anti-inflammatory drugs (NSAIDs) and sulfonyl compounds. Real concern grows once this chemical makes it into a person’s daily regimen—especially if that routine already features heart medicine, antibiotics, or blood thinners.
Some drugs with similar backbone structures have shown interactions before. Those on warfarin, for instance, run into trouble with many sulfonyl-based drugs. The risk isn’t just academic; bruising or unexplained bleeding causes real discomfort and sends people to the ER. Drugs for high blood pressure also sometimes trigger problems, especially when another substance enters the mix—blood pressure can plummet below safe levels, leaving people dizzy or faint.
A few years back, a patient brought a brand-new prescription containing a sulfonyl group. The prescription seemed fine on paper, but she also picked up a medicine for her rheumatoid arthritis and a common antibiotic. Two weeks later, she described feeling lightheaded and had fresh, unexplained bruises. It turned out the drugs all fought over liver enzymes—the body’s cleanup crew. Stacking medications with similar metabolic paths can flood the system or cause levels to skyrocket. This story happens more than it should, and not just to those juggling a dozen pills.
Currently, peer-reviewed research on Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate focuses on its effectiveness in early lab tests. Most trials haven’t covered what happens when patients already use medications like metformin or SSRIs. Scientists often rely on animal models and predictions from known relatives. An oversight in this stage can spill into the real world, especially once larger groups begin using new treatment options.
People in healthcare sometimes lean on computer checks or printed reference sheets. Those tools help, but they only scan for interactions that already show up in clinical trials or case reports. Once a new chemical enters the market, everyone becomes part of a giant experiment. Only candid conversations between patients and providers catch things before harm occurs. A simple “What else do you take each day?” makes all the difference. That question saved a friend’s mother after she started a new antifungal medication—her blood pressure medication reacted in a way nobody saw coming.
Trying new medication carries risk, but that risk shrinks when clinicians and patients work together. Reading up on side effects, not skipping questions at the doctor’s office, and tracking changes in how the body feels can shift the odds. Providers benefit by reviewing patient lists regularly and cross-referencing new drugs for enzymatic or metabolic overlap. If a person notices sudden bruising, fatigue, or stomach pain, getting help early often stops trouble before it grows.
Crowdsourcing data and using electronic health records intelligently help track rare drug interactions. Clinicians need reminders about drugs that carry similar structures. More transparency among researchers, pharmacists, and frontline nurses can build a safety net around complex molecules. As more compounds hit the market, old-fashioned listening and communication often keep people safe. Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate may be new, but the process for preventing harm has rarely changed—teamwork and vigilance still matter most.
Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate isn’t something most people run across during routine errands. This lengthy name stands for a complex molecule often connected to research labs, rare medications, or highly specific scientific projects. Composer of chemicals like this usually points to a background in pharmacology or advanced chemistry. On my visits to laboratories over the years, I noticed professionals pay close attention to the chain of custody for substances with potential pharmacological action. With new molecules, the safety profile often stays incomplete for years.
In my early days working with hospital pharmacists, I watched them weigh the risks and benefits of new drugs. Prescription rules did not simply pop up out of an urge to complicate life for others. They draw a protective line so powerful chemicals reach only those who know their potential and limitations. With substances like Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate, one mistake in dose or application could lead to health issues. Responsible access is not about cynically locking the door, but keeping people from slipping on an invisible patch of ice.
Today, plenty of people can order compounds over the internet. Digital access puts chemistry sets just a click away. Oversight—the sort seen in regulated pharmacies—creates an extra layer of review before handing over anything with potential for harm. Is that annoying? Sometimes. But I recall stories from healthcare colleagues about people turning up ill because they took a shortcut, ordered something online, and found out too late about a rare side effect or interaction.
Easy sales open up a can of worms. Non-experts face big risks with synthetic chemicals whose effects may not show up until days or weeks later. Without professional input, guessing a safe dose based on scattered information often leads to trouble. Written prescriptions come from people who know this field, who stay current with safety updates, adverse event alerts, and dosing guidelines.
Manufacturing standards also come into play. Prescription-only status means batches run through checks for strength and purity. I have seen firsthand in compounding pharmacies how rigorous those checks can be, especially where rare synthetic substances get handled.
Prescription requirements link back to research findings and toxicology data. For experimental or uncommon compounds, real-world studies may not exist yet. The precautionary principle keeps dangerous missteps from becoming headlines or, worse, another patient cautionary tale. Regulatory bodies, including the FDA and EMA, rarely greenlight open sales until mountains of data support both safety and benefit.
Public curiosity fuels searches for experimental compounds. Patients tired of existing options poke around for something new—sometimes out of frustration, sometimes out of hope. The answer is not to loosen controls. Instead, more direct communication with physicians, affordable access to specialist consults, and reliable drug information resources can help cut out dangerous guesswork. If new treatments show promise, continuing clinical trials and quickened regulatory pathways may soon offer safer access.
Bottom line: Most countries keep Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate behind a prescription counter for patient safety. Experience, facts, and regulatory oversight line up behind this decision, not just to frustrate, but to protect lives—and keep the pharmacy out of the emergency room.![Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate](/static/81c4c90b-3bfe-4770-bbec-fcbf5e0a3809/images/2d/sodium-2-4-3-4-chlorophenyl-4-5-dihydro-1h-pyrazol-1-yl-phenyl-sulphonyl-ethanesulphonate.png)
![Sodium 2-[[4-[3-(4-Chlorophenyl)-4,5-Dihydro-1H-Pyrazol-1-Yl]Phenyl]Sulphonyl]Ethanesulphonate](/static/81c4c90b-3bfe-4770-bbec-fcbf5e0a3809/images/3d/sodium-2-4-3-4-chlorophenyl-4-5-dihydro-1h-pyrazol-1-yl-phenyl-sulphonyl-ethanesulphonate.gif)
| Names | |
| Preferred IUPAC name | Sodium 2-{[4-[3-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-1-yl]phenyl]sulfonyl}ethane-1-sulfonate |
| Other names |
Sulfinpyrazone sodium Anturane sodium salt Sodium sulfinpyrazone |
| Pronunciation | /ˈsəʊdiəm tuː ˈfɔːr brækt ɹiː θriː dæʃ ˈfɔː ˈklɔːrəˌfɛnɪl dæʃ ˈfɔːr ˈfaɪv daɪˈhaɪdrəʊ wʌn eɪtʃ paɪˈræzɒl wʌn waɪ ɛl brækt ˈfiːnɪl sʌlˈfəʊnɪl ˈɛθəneɪn sʌlˈfəʊneɪt/ |
| Identifiers | |
| CAS Number | 144689-63-4 |
| 3D model (JSmol) | `CN1N=CC(C1C2=CC=C(C=C2)S(=O)(=O)CCS(=O)(=O)[O-])C3=CC=C(C=C3)Cl.[Na+]` |
| Beilstein Reference | 6902256 |
| ChEBI | CHEBI:90267 |
| ChEMBL | CHEMBL1201199 |
| ChemSpider | 25380278 |
| DrugBank | DB07972 |
| ECHA InfoCard | 03-2119-0062 |
| Gmelin Reference | 1171348 |
| KEGG | C11215 |
| MeSH | D015242 |
| PubChem CID | 16222202 |
| RTECS number | VX8226000 |
| UNII | YFZ4V57POE |
| UN number | Not regulated |
| Properties | |
| Chemical formula | C17H16ClN3O6S2Na |
| Molar mass | 613.08 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.55 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -1.6 |
| Vapor pressure | Negligible |
| Acidity (pKa) | -2.1 |
| Basicity (pKb) | 12.98 |
| Magnetic susceptibility (χ) | -66.0·10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.602 |
| Dipole moment | 5.52 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 679.67 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -759.7 kJ/mol |
| Pharmacology | |
| ATC code | M01AX05 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS07, GHS09 |
| Pictograms | GHS05,GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P264, P280, P305+P351+P338, P337+P313 |
| Flash point | > 230.7 °C |
| Lethal dose or concentration | LD₅₀ oral rat >2000 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse (oral) 2200 mg/kg |
| PEL (Permissible) | Not established |
| REL (Recommended) | 250mg |
| IDLH (Immediate danger) | NIOSH: Not Listed |
| Related compounds | |
| Related compounds |
Sodium sulfacetamide Sodium sulfanilate Sodium p-toluenesulfonate Sodium 4-chlorobenzenesulfonate Sodium ethane-1-sulfonate Sulfa drugs (general class) chlorophenylpyrazoles Sulfonamide derivatives |
